FASN inhibits ferroptosis in breast cancer via USP5 palmitoylation-dependent regulation of GPX4 deubiquitination

Zhiwen Qian, Ying Jiang, Yun Cai, Erli Gao, Cenzhu Wang, Jianfeng Dong, Fengxu Wang, Lu Liu, Danping Wu, Feng Zhang, Yida Wang, Xin Ning, Qi Li, Yilan You, Yanfang Gu, Jie Mei, Xinyuan Zhao, Yan ZhangJournal of Experimental & Clinical Cancer Research 2025 · DOI

TL;DR

This study reveals a novel mechanism by which Fatty Acid Synthase (FASN) suppresses ferroptosis in breast cancer. FASN promotes the palmitoylation of USP5, a deubiquitinase, which in turn stabilizes GPX4, a key ferroptosis regulator. Inhibiting FASN with orlistat enhances ferroptosis and boosts the effectiveness of anti-PD-1 immunotherapy, suggesting a promising therapeutic strategy.

What Problem Does This Paper Address?

Breast cancer (BC) remains a major health challenge, and while immunotherapy has shown promise, many patients don't respond effectively, often due to an "immune-cold" tumor microenvironment. Ferroptosis, a form of programmed cell death linked to lipid metabolism, has emerged as a potential strategy to overcome this resistance. However, the precise molecular mechanisms by which metabolic enzymes like FASN influence ferroptosis in BC were unclear. This paper aims to bridge this gap by investigating the role of FASN in regulating ferroptosis and its implications for immunotherapy response in breast cancer.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics Analysis: They utilized public datasets (TCGA, GEO) to analyze FASN expression patterns, its correlation with clinical characteristics, and its association with immune microenvironment features.
  • Cellular Assays: Standard cell culture techniques were used for transfection (siRNA, plasmids), proliferation assays (CCK-8, colony formation), migration and invasion assays (Transwell), apoptosis detection (TUNEL), and Western blotting to assess protein levels.
  • Biochemical Techniques:
    • Co-immunoprecipitation (Co-IP) and Mass Spectrometry (IP-MS): Used to identify proteins interacting with GPX4 and to confirm USP5-GPX4 interactions.
  • Ubiquitination Assays: To determine the effect of USP5 knockdown and FASN inhibition on GPX4 ubiquitination.
  • Acyl-Biotin Exchange (ABE) Assay: To detect and quantify protein S-palmitoylation.
  • In Vivo Studies: Mouse models (4T1 mammary tumors in BALB/c mice) were used to evaluate the therapeutic efficacy of FASN inhibition (orlistat) combined with anti-PD-1 immunotherapy.
  • Immunofluorescence (IF) and Immunohistochemistry (IHC): To visualize the expression and localization of key proteins (FASN, USP5, GPX4, CD8) in cells and tissue samples.
  • Protein-Protein Docking: Computational methods were used to predict the 3D complex model and potential interaction domains between USP5 and GPX4.

Datasets

  • TCGA-BRCA dataset: Used for transcriptomic sequencing (RNA-seq) and clinical data of 1,069 breast cancer patients.
  • GEO database:
    • GSE180286: Single-cell RNA sequencing (scRNA-seq) data from 5 primary breast cancer tumors.
  • GSE194040 (95 cases) and GSE173839 (72 cases): Gene expression profiles from breast cancer immunotherapy cohorts.
  • Human Protein Atlas (HPA) database: Used for immunohistochemistry images of FASN in tumor and stromal cells.

Key Insights and Ideas

  • FASN as an Immune-Cold Driver: The study establishes a strong link between high FASN expression and an "immune-cold" tumor microenvironment in breast cancer, characterized by reduced immune cell infiltration and suppressed immune signaling. This suggests FASN actively contributes to immune evasion.
  • USP5 as a GPX4 Stabilizer: A critical finding is the identification of USP5 as a deubiquitinase that directly interacts with and stabilizes GPX4, a crucial protein for preventing ferroptosis.
  • Palmitoylation as the Missing Link: The research uncovers that FASN's influence on USP5-GPX4 interaction is mediated by USP5 S-palmitoylation. FASN promotes this modification, which enhances USP5's binding to GPX4, thereby preventing GPX4 degradation.
  • Therapeutic Synergy: Combining a FASN inhibitor (orlistat) with anti-PD-1 immunotherapy significantly suppressed tumor growth in vivo, highlighting the potential of this combination strategy.

Key Results

  • FASN expression positively correlates with tumor purity and negatively with immune and T-cell inflammation scores in breast cancer.
  • FASN knockdown in BC cells significantly induces lipid peroxidation and decreases GPX4 levels, leading to ferroptosis.
  • USP5 was identified as a direct interactor of GPX4, and its knockdown led to reduced GPX4 protein levels.
  • FASN knockdown inhibits USP5 S-palmitoylation, reducing USP5-GPX4 interaction and increasing GPX4 ubiquitination and degradation.
  • In vivo studies showed that orlistat combined with anti-PD-1 therapy significantly suppressed tumor growth and increased CD8+ T cell infiltration.
  • Orlistat treatment alone enhanced ferroptosis and increased tumor sensitivity to immunotherapy.

Limitations and Future Work

  • Mechanism of FASN-Mediated Palmitoylation: While the study demonstrates that FASN regulates USP5 palmitoylation, the precise molecular mechanism by which FASN influences this process remains to be fully elucidated and is identified as an area for future investigation.
  • Dosing and Duration of FASN Inhibition: The study notes that orlistat treatment in vitro did not induce apoptosis to the same extent as FASN knockdown, suggesting that FASN might regulate apoptosis through mechanisms independent of its lipogenic activity. This implies that careful consideration of dosing and treatment duration is needed for combination therapies involving FASN inhibitors.
  • Broader Applicability: While the study focuses on breast cancer, further research could explore whether these FASN-USP5-GPX4 axis mechanisms are conserved in other cancer types.
  • Clinical Translation: Further clinical trials are warranted to validate the therapeutic potential of FASN inhibition in combination with immunotherapy for breast cancer patients.

Summary updated

Abstract

Increasing studies have reported that dysregulated lipid metabolism is an independent risk factor for breast cancer (BC); it would be, therefore, enlightening to investigate the relationship between metabolic reprogramming and the tumor microenvironment in the future. Ferroptosis, a novel form of programmed cell death, is characterized by glutathione (GSH) depletion and inactivation of glutathione peroxidase 4 (GPX4), the central regulator of the antioxidant system. While the close association between fatty acid metabolism and ferroptosis has been studied in various diseases, the interplay between the key fatty acid metabolic enzyme fatty acid synthase (FASN) and ferroptosis in BC remains unexplored. At the beginning of the current study, we demonstrated that FASN expression positively correlates with an immune-cold tumor microenvironment in BC. Subsequent findings revealed that FASN knockdown promotes GPX4 degradation-induced ferroptosis, thereby enhancing the efficacy of anti-programmed cell death protein 1 (PD-1) immunotherapy. Co-immunoprecipitation coupled with mass spectrometry (IP/MS) and co-IP experiments demonstrated that ubiquitin specific protease 5 (USP5) stabilizes GPX4 by binding to and deubiquitinating it. Furthermore, knockdown of FASN inhibited the palmitoylation of USP5, reducing its interaction with GPX4 and consequently increasing GPX4 ubiquitination and degradation. Our results demonstrate that FASN suppresses ferroptosis in BC by stabilizing GPX4 via USP5-mediated mechanisms, highlighting FASN inhibition as a potential therapeutic approach to enhance immunotherapy response.
BibTeX
@article{qian2025fasn,
  author = {Zhiwen Qian and Ying Jiang and Yun Cai and Erli Gao and Cenzhu Wang and Jianfeng Dong and Fengxu Wang and Lu Liu and Danping Wu and Feng Zhang and Yida Wang and Xin Ning and Qi Li and Yilan You and Yanfang Gu and Jie Mei and Xinyuan Zhao and Yan Zhang},
  title = {{FASN inhibits ferroptosis in breast cancer via USP5 palmitoylation-dependent regulation of GPX4 deubiquitination}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2025},
  doi = {10.1186/s13046-025-03548-8},
}
Figure